Top
Summary
All studies
Mortality
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
 
Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
c19early.org COVID-19 treatment researchIbrutinibIbrutinib (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Outcomes in COVID-19 ibrutinib studies

0 0.5 1 1.5+ All studies -9% 1 46 Improvement, Studies, Patients Relative Risk Mortality -9% 1 46 RCTs -9% 1 46 Late -9% 1 46 Ibrutinib for COVID-19 c19early.org May 2025 Favorsibrutinib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Woyach (RCT) unknown, >2 years late 10 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 study (+1 unreported RCT) c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 mortality result c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 serious outcome c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] no disch. 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 recovery result c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Woyach (RCT) unknown, >2 years late 10 (total) Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 Randomized Controlled Trial c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 RCT mortality result c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Late treatment -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk All studies -9% 1.09 [0.07-16.4] 1/22 1/24 9% higher risk 1 ibrutinib COVID-19 peer reviewed studies c19early.org May 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors ibrutinib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] death 1/22 1/24 Improvement, RR [CI] Treatment Control iNSPIRE Coutre (DB RCT) -209% 3.09 [0.13-72.1] death 1/22 0/24 iNSPIRE Coutre (DB RCT) -9% 1.09 [0.07-16.4] no disch. 1/22 1/24 iNSPIRE Coutre (DB RCT) 35% 0.65 [0.18-2.42] progression 3/22 5/24 Ibrutinib COVID-19 outcomes c19early.org May 2025 Favors ibrutinib Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit